Insights & Resources
Perspectives, reports, and research from the Atacana team built for the senior leaders navigating the most complex commercial decisions in the industry.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Explore Our Content
Rezdiffra: SWOT Analysis and Strategic Evaluation
Atacana Group
•
May 31, 2024
Big strides in MASH treatment with Madrigal Pharmaceuticals’ Rezdiffra! But… is this the best there is?
Reports
Strategy
Cardiovascular
Antibacterial Vaccines Catalysts
Atacana Group
•
May 8, 2024
Explore the future of the global antibacterial vaccine market, anticipating growth from $22B to $40B by 2030, unveiling a lucrative landscape ripe for innovation.
Reports
Vaccines
Antiviral Vaccines 2024 & 2025 Catalysts Report
Atacana Group
•
April 19, 2024
The Leading companies in the Antiviral Vaccine market, such as Pfizer, Moderna, GSK, and AstraZeneca are anticipating pivotal advancements, including regulatory milestones, clinical trial updates, and strategic product launches.
Reports
Vaccines
Multiple Sclerosis: Large market with unmet need
Atacana Group
•
November 1, 2023
Current treatment options available (major therapeutics classes approved include interferons, S1p modulators, and antibodies against integrins, CD20 or CD52) are limited for progressive MS treatment.
Reports
Neuroscience
Navigating Uncharted Waters: A Fresh Perspective on Rare Disease Treatment Launches
Atacana Group
•
October 10, 2023
The rare disease landscape has changed over the last several years.
Reports
Rare Diseases
.avif)